Physician profile
Jay Pyrtle
NPI 1285804419
$2,925.07
in general payments reported to CMS, 2019-2025
28 companies · $628 in 2025
The $628 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $54.09 · 2021: $274 · 2022: $437 · 2023: $449 · 2024: $760 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,753 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,752.68 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $552.40 | 2019-2025 | |
| Janssen Biotech, INC. | $419.05 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $310.16 | 2019-2024 | Xifaxan |
| Pfizer INC. | $300.65 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $249.85 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $164.36 | 2021-2023 | Zeposia |
| Medtronic, INC. | $102.55 | 2024 | Gi Genius |
| Aimmune Therapeutics, INC. | $68.66 | 2024-2025 | Zenpep |
| Genzyme Corporation | $67.51 | 2023-2025 | |
| Shionogi INC | $61.00 | 2019 | |
| Ucb, INC. | $56.26 | 2019 | |
| Lilly USA, LLC | $53.90 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $53.48 | 2023-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $50.54 | 2022-2023 | Ocaliva |
| Ardelyx, INC. | $43.84 | 2024-2025 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $41.20 | 2023-2024 | Idacio |
| Madrigal Pharmaceuticals | $40.86 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $40.57 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $39.25 | 2024 | Iqirvo |
| Ferring Pharmaceuticals INC. | $35.44 | 2022-2023 | Rebyota |
| Redhill Biopharma INC. | $34.91 | 2020-2021 | |
| Cook Medical LLC | $29.92 | 2025 | Hemospray |
| Braintree Laboratories, INC. | $24.76 | 2020-2021 | |
| Endogastric Solutions, INC | $22.42 | 2019 | |
| Echosens North America, INC. | $17.42 | 2025 | Fibroscan |
| Regeneron Healthcare Solutions, INC. | $17.36 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $14.11 | 2021 | |
| Qol Medical, LLC | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Pyrtle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.